Quantitative EEG and Cognitive Decline in Parkinson's Disease
Vitalii V Cozac1, Ute Gschwandtner1, Florian Hatz1
1Universitätsspital Basel, Abteilung Neurophysiologie, Petersgraben 4, 4031 Basel, Switzerland.
Parkinson'S Disease
|May 6, 2016
Summary
Quantitative EEG (QEEG) shows promise in predicting cognitive decline in Parkinson's disease (PD). QEEG markers can differentiate PD patients' cognitive states and predict dementia risk effectively.
Area of Science:
- Neuroscience
- Neurology
- Biomarkers
Background:
- Cognitive decline and dementia are prevalent in Parkinson's disease (PD).
- Identifying reliable biomarkers for cognitive impairment in PD is crucial.
- Quantitative EEG (QEEG) has emerged as a potential tool for assessing cognitive status.
Purpose of the Study:
- To review and analyze recent publications on the predictive value of QEEG for cognitive decline in PD.
- To outline the fundamental principles of QEEG analysis in the context of PD.
Main Methods:
- A systematic literature search of the MEDLINE database was conducted from January 1, 2005, to March 2, 2015.
- Twenty-four studies reporting QEEG findings in PD patients with varying cognitive states were analyzed.
Main Results:
- QEEG spectral and connectivity markers can distinguish between PD patients with different levels of cognitive decline.
- QEEG variables correlate with longitudinal cognitive assessment tools and predict PD-related dementia risk.
- QEEG analysis demonstrates high test-retest reliability and is noninvasive.
Conclusions:
- QEEG is a promising, reliable, and noninvasive biomarker for predicting cognitive decline and dementia in Parkinson's disease.
- QEEG offers advantages over traditional neuropsychological testing due to its resistance to learning effects.
